Axel Oberemm

Axel Oberemm

Auto-generated profile, based on publicly available information

Axel Oberemm

Federal Institute for Risk Assessment, Berlin, Germany

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1998 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
SPStephan Pflugmacher
Stephan Pflugmacher
CWClaudia Wiegand
Claudia Wiegand
AOAxel Oberemm
Axel Oberemm
KBKenneth A. Beattie
Kenneth A. Beattie
EKEberhard Krause
Eberhard Krause
CSChristian Steinberg
Christian Steinberg

14 January 1999 in Environmental Toxicology
Verified
Journal Article
Closed access
PDF file
AOA. Oberemm
A. Oberemm
JBJ. Becker
J. Becker
GCG. A. Codd
G. A. Codd
CSC. Steinberg
C. Steinberg

1 November 1997 in Water Research
Verified
Journal Article
Closed access
AOAxel Oberemm
Axel Oberemm
JFJutta Fastner
Jutta Fastner
CSChristian E.W. Steinberg
Christian E.W. Steinberg

16 November 2014 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
MGMarianna Grinberg
Marianna Grinberg
RSRegina M. Stöber
Regina M. Stöber
KEKarolina Edlund
Karolina Edlund
EREugen Rempel
Eugen Rempel
PGPatricio Godoy
Patricio Godoy
Jan G HengstlerJan G Hengstler
Jan G Hengstler

29 December 2012 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
MSMarkus Schug
Markus Schug
RSRegina Stöber
Regina Stöber
THTanja Heise
Tanja Heise
HMHans Mielke
Hans Mielke
UGUrsula Gundert-Remy
Ursula Gundert-Remy
Jan G HengstlerJan G Hengstler
Jan G Hengstler

1 June 2021 in Environmental Research
Verified
Journal Article
Open access
CVCélia Ventura
Célia Ventura
BGBruno Costa Gomes
Bruno Costa Gomes
AOAxel Oberemm
Axel Oberemm
Henriqueta LouroHenriqueta Louro
Henriqueta Louro
PHPasi Huuskonen
Pasi Huuskonen
MSMaria Joao Silva
Maria Joao Silva
A number of human biomonitoring (HBM) studies have presented data on exposure to hexavalent chromium [Cr(VI)] and cadmium (Cd), but comparatively few include results on effect biomarkers. The latter are needed to identify associations between exposure and adverse outcomes (AOs) in order to assess public health implications. To support improved derivation of EU regulation and policy making, it is of great importance to identify the most reliable effect biomarkers for these heavy metals that can be used in HBM studies. In the framework of the Human Biomonitoring for Europe (HBM4EU) initiative, our study aim was to identify effect biomarkers linking Cr(VI) and Cd exposure to selected AOs including cancer, immunotoxicity, oxidative stress, and omics/epigenetics. A comprehensive PubMed search identified recent HBM studies, in which effect biomarkers were examined. Validity and applicability of the markers in HBM studies are discussed. The most frequently analysed effect biomarkers regarding Cr(VI) exposure and its association with cancer were those indicating oxidative stress (e.g., 8-hydroxy-2'-deoxyguanosine (8-OHdG), malondialdehyde (MDA), glutathione (GSH)) and DNA or chromosomal damage (comet and micronucleus assays). With respect to Cd and to some extent Cr, β-2-microglobulin (B2-MG) and N-acetyl-β-D-glucosaminidase (NAG) are well-established, sensitive, and the most common effect biomarkers to relate Cd or Cr exposure to renal tubular dysfunction. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule (KIM)-1 could serve as sensitive biomarkers of acute kidney injury in response to both metals, but need further investigation in HBM studies. Omics-based biomarkers, i.e., changes in the (epi-)genome, transcriptome, proteome, and metabolome associated with Cr and/or Cd exposure, are promising effect biomarkers, but more HBM data are needed to confirm their significance. The combination of established effect markers and omics biomarkers may represent the strongest approach, especially if based on knowledge of mechanistic principles. To this aim, also mechanistic data were collected to provide guidance on the use of more sensitive and specific effect biomarkers. This also led to the identification of knowledge gaps relevant to the direction of future research.